[1] | Qiulu ZHANG, Zhuo LI, Congrong LIU, Limei GUO. Components of tumor stroma-immune microenvironment and their interactions in intrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2025, 41(3): 594-600. doi: 10.12449/JCH250331 |
[2] | Xiaoli LIU, Qinwen TAN, Jian XU, Huanling CHEN, Jie YU, Lu LU, Mingkan DAI, Jingjing HUANG, Hongna HUANG, Dewen MAO. Effect of amino acid metabolic reprogramming on immune microenvironment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(12): 2531-2537. doi: 10.12449/JCH241226 |
[3] | Jiannan QIU, Peng WANG, Yin CAO, Zhongxia WANG, Junhua WU, Chunping JIANG. Effect of kinesin family member 15 on the proliferation of hepatocellular carcinoma cells and its mechanism of action[J]. Journal of Clinical Hepatology, 2024, 40(2): 327-334. doi: 10.12449/JCH240217 |
[4] | Peng WANG, Jiannan QIU, Zhongxia WANG, Junhua WU, Chunping JIANG. Research advances in tumor-associated macrophages in hepatocellular carcinoma microenvironment[J]. Journal of Clinical Hepatology, 2023, 39(5): 1212-1218. doi: 10.3969/j.issn.1001-5256.2023.05.033 |
[5] | Shun CHEN, Jun WANG. Advances in tumor microenvironment and immunotherapy of Cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2022, 38(10): 2428-2432. doi: 10.3969/j.issn.1001-5256.2022.10.044 |
[6] | Yiyi ZHANG, Min XU. Research advances in the mechanism of tumor microenvironment in pancreatic cancer and related targeted therapy[J]. Journal of Clinical Hepatology, 2022, 38(4): 965-968. doi: 10.3969/j.issn.1001-5256.2022.04.046 |
[7] | GUT|FOXA2 prevents hyperbilirubinaemia in acute liver failure by maintaining apical MRP2 expression[J]. Journal of Clinical Hepatology, 2022, 38(7): 1619-1619. doi: 10.3969/j.issn.1001-5256.2022.07.gwjpwzjj2 |
[8] | Fan YAO, Xin YIN. Regulatory effect of immune checkpoint TIGIT/CD155 on the immune microenvironment of primary liver cancer and its application prospects[J]. Journal of Clinical Hepatology, 2022, 38(11): 2632-2635. doi: 10.3969/j.issn.1001-5256.2022.11.039 |
[9] | Mingqiang ZHU, Youming DING. Current status of the research on microenvironment-targeting therapy and immunotherapy for liver cancer[J]. Journal of Clinical Hepatology, 2022, 38(8): 1913-1917. doi: 10.3969/j.issn.1001-5256.2022.08.038 |
[10] | Mengkui HAN, Jin LI, Xiaohua YANG. Function and regulatory mechanism of T lymphocytes in tumor immune microenvironment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(11): 2621-2626. doi: 10.3969/j.issn.1001-5256.2022.11.037 |
[11] | Guangjun TANG, Jing YOU, Huai'e LIU, Yujuan PENG. Role of T helper 17 cell/regulatory T cell imbalance in the progression of HBV-related liver diseases[J]. Journal of Clinical Hepatology, 2021, 37(2): 414-418. doi: 10.3969/j.issn.1001-5256.2021.02.035 |
[12] | Xueyan LI, Changjun WANG. Influence of hepatocellular carcinoma microenvironment on myeloid-derived suppressor cells[J]. Journal of Clinical Hepatology, 2021, 37(6): 1473-1476. doi: 10.3969/j.issn.1001-5256.2021.06.053 |
[13] | Zherui LIU, Xiaodong JIA, Yinying LU. Research advances in hepatocellular carcinoma-related imbalance of bile acid metabolism and related regulatory mechanism[J]. Journal of Clinical Hepatology, 2021, 37(3): 690-694. doi: 10.3969/j.issn.1001-5256.2021.03.038 |
[14] | Wang DanDan, Song Jia, Zhang XiaoLan. Research advances in the role of gut microbiota in liver diseases[J]. Journal of Clinical Hepatology, 2019, 35(9): 2120-2123. doi: 10.3969/j.issn.1001-5256.2019.09.053 |
[15] | Xu Ying, Zhang DingQi, Chen JiaMei, Liu Wei, Liu Ping. Effect of various cells on the activation of hepatic stellate cells in liver microenvironment[J]. Journal of Clinical Hepatology, 2019, 35(2): 424-430. doi: 10.3969/j.issn.1001-5256.2019.02.042 |
[17] | Ni Qian, Wan FengQi, Dong XiangYu, Zhang YouCheng. Impact of high-altitude exposure on hepatic gluconeogenesis in rats[J]. Journal of Clinical Hepatology, 2015, 31(9): 1477-1480. doi: 10.3969/j.issn.1001-5256.2015.09.027 |
[20] | Chen Zhong, Ni JiaLian, Liu LuYue, Yan JianJun, Huang Liang, Yan YiQun. The relationship between CD4+CD25+ regulatory T Cells and T lymphocytes immunity in tumor microenvironment of hepatocellular carcinoma.[J]. Journal of Clinical Hepatology, 2008, 24(1): 38-40. |